| 0.9389 -0.018 (-1.92%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.19 |
1-year : | 1.34 |
| Resists | First : | 1.02 |
Second : | 1.14 |
| Pivot price | 0.91 |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 0.94 |
| MA(100) : | 1.27 |
MA(250) : | 1.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 28.4 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 2.3 | Low : | 0.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ATOS ] has closed below upper band by 33.5%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.98 - 0.98 | 0.98 - 0.99 |
| Low: | 0.86 - 0.87 | 0.87 - 0.87 |
| Close: | 0.95 - 0.96 | 0.96 - 0.97 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Thu, 23 Jan 2025
Atossa Therapeutics reports progress in breast cancer treatments - Investing.com India
Thu, 23 Jan 2025
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - GlobeNewswire
Thu, 23 Jan 2025
Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan
Mon, 06 Jan 2025
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Wed, 11 Dec 2024
Atossa's Endoxifen Shows Dramatic 23.5% Breast Density Reduction in Phase 2 Clinical Trial Results - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 28.1 (%) |
| Shares Short | 8,200 (K) |
| Shares Short P.Month | 12,450 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.4 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -4.53 |
| PEG Ratio | 0 |
| Price to Book value | 1.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|